Treatment Optimization and Management of AEs with Enfortumab Vedotin + Pembrolizumab for Untreated Locally Advanced/Metastatic Urothelial Cancer: A Podcast.

IF 3.2 Q2 ONCOLOGY

Oncology and Therapy Pub Date : 2025-08-15 DOI:10.1007/s40487-025-00369-9

Thomas Powles, Maria Lapuente, Benjamin Garmezy

{"title":"Treatment Optimization and Management of AEs with Enfortumab Vedotin + Pembrolizumab for Untreated Locally Advanced/Metastatic Urothelial Cancer: A Podcast.","authors":"Thomas Powles, Maria Lapuente, Benjamin Garmezy","doi":"10.1007/s40487-025-00369-9","DOIUrl":null,"url":null,"abstract":"<p><p>In the EV-302/KEYNOTE-A39 trial (NCT04223856), enfortumab vedotin + pembrolizumab (EV + P) became the first treatment in decades to demonstrate significant survival benefit compared with platinum-based chemotherapy in the first-line setting for patients with locally advanced or metastatic urothelial cancer. The safety profile of EV + P in EV-302/KEYNOTE-A39 was consistent with previous clinical studies and with the expected safety profiles of each agent alone; however, real-world experience in the management of adverse events (AEs) resulting from treatment with EV + P in patients with locally advanced or metastatic urothelial cancer is still evolving. Historically, healthcare professionals have been familiar with the management of EV and pembrolizumab as monotherapies, with guidance available for management of AEs with either drug alone. However, management of AEs with EV + P can sometimes be more complex since some of the AEs associated with EV also occur with pembrolizumab. Such AEs include skin reactions, hyperglycemia, and pneumonitis, all of which have been reported with either therapy alone and with increased incidence with the combination. In this podcast, we discuss the management of AEs with EV + P on the basis of our personal experiences with clinical trials and in our practices and provide perspectives for healthcare professionals on practical management of common AEs and effective dose management strategies. This may help improve the patient experience and allow patients to stay on therapy for longer, leading to optimized treatment outcomes. Podcast video (MP4 3,14,449 kb).</p>","PeriodicalId":44205,"journal":{"name":"Oncology and Therapy","volume":" ","pages":""},"PeriodicalIF":3.2000,"publicationDate":"2025-08-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Oncology and Therapy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1007/s40487-025-00369-9","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

In the EV-302/KEYNOTE-A39 trial (NCT04223856), enfortumab vedotin + pembrolizumab (EV + P) became the first treatment in decades to demonstrate significant survival benefit compared with platinum-based chemotherapy in the first-line setting for patients with locally advanced or metastatic urothelial cancer. The safety profile of EV + P in EV-302/KEYNOTE-A39 was consistent with previous clinical studies and with the expected safety profiles of each agent alone; however, real-world experience in the management of adverse events (AEs) resulting from treatment with EV + P in patients with locally advanced or metastatic urothelial cancer is still evolving. Historically, healthcare professionals have been familiar with the management of EV and pembrolizumab as monotherapies, with guidance available for management of AEs with either drug alone. However, management of AEs with EV + P can sometimes be more complex since some of the AEs associated with EV also occur with pembrolizumab. Such AEs include skin reactions, hyperglycemia, and pneumonitis, all of which have been reported with either therapy alone and with increased incidence with the combination. In this podcast, we discuss the management of AEs with EV + P on the basis of our personal experiences with clinical trials and in our practices and provide perspectives for healthcare professionals on practical management of common AEs and effective dose management strategies. This may help improve the patient experience and allow patients to stay on therapy for longer, leading to optimized treatment outcomes. Podcast video (MP4 3,14,449 kb).

查看原文本刊更多论文

对未治疗的局部晚期/转移性尿路上皮癌，使用Enfortumab Vedotin + Pembrolizumab治疗ae的优化和管理：Podcast

在EV-302/KEYNOTE-A39试验（NCT04223856）中，与以铂为基础的化疗相比，enfortumab vedotin + pembrolizumab （EV + P）成为几十年来首个在一线治疗局部晚期或转移性尿路上皮癌患者时显示显着生存获益的治疗方法。EV-302/KEYNOTE-A39中EV + P的安全性与先前的临床研究一致，也与每种药物单独使用的预期安全性一致；然而，对于局部晚期或转移性尿路上皮癌患者使用EV + P治疗导致的不良事件（ae）管理的实际经验仍在不断发展。从历史上看，医疗保健专业人员已经熟悉了EV和派姆单抗作为单一治疗的管理，并提供了单独使用任何一种药物管理ae的指导。然而，EV + P的ae的管理有时可能更复杂，因为一些与EV相关的ae也发生在派姆单抗上。这些不良反应包括皮肤反应、高血糖和肺炎，所有这些都是单独治疗时报道的，联合治疗时发病率增加。在本播客中，我们根据个人临床试验和实践经验，讨论EV + P急性发作的管理，并为医疗保健专业人员提供常见急性发作的实际管理和有效剂量管理策略的观点。这可能有助于改善患者的体验，使患者能够更长时间地接受治疗，从而获得最佳的治疗效果。播客视频（mp4.3,14,449 kb）。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Oncology and Therapy ONCOLOGY-

CiteScore

3.40

自引率

0.00%

发文量

审稿时长

6 weeks

期刊介绍： Now indexed in PubMed Aims and Scope Oncology and Therapy is an international, peer reviewed, rapid-publication (peer review in 2 weeks, published 3–4 weeks from acceptance) journal dedicated to the publication of high-quality pre-clinical, clinical (all phases), observational, real-world, and health outcomes research around the discovery, development, and use of therapeutics and interventions (including devices) across all therapeutic areas. Studies relating to diagnostics and diagnosis, pharmacoeconomics, public health, epidemiology, quality of life, and patient care, management, and education are also encouraged. The journal is of interest to a broad audience of healthcare professionals and publishes original research, reviews, communications and letters. The journal is read by a global audience and receives submissions from all over the world. Oncology and Therapy will consider all scientifically sound research be it positive, confirmatory or negative data. Submissions are welcomed whether they relate to an international and/or a country-specific audience, something that is crucially important when researchers are trying to target more specific patient populations. This inclusive approach allows the journal to assist in the dissemination of all scientifically and ethically sound research. Rapid Publication The journal’s rapid publication timelines aim for a peer review decision within 2 weeks of submission. If an article is accepted it will be published online 3-4 weeks from acceptance. These rapid timelines are achieved through the combination of a dedicated in-house editorial team, who closely manage article workflow, and an extensive Editorial and Advisory Board who assist with rapid peer review. This allows the journal to support the rapid dissemination of research, whilst still providing robust peer review. Combined with the journal’s open access model this allows for the rapid and efficient communication of the latest research and reviews, allowing the advancement of clinical therapies. Personal Service The journal’s dedicated in-house editorial team offer a personal “concierge service” meaning that authors will always have a personal point of contact able to update them on the status of their manuscript. The editorial team check all manuscripts to ensure that articles conform to the most recent COPE, GPP and ICMJE publishing guidelines. This supports the publication of ethically sound and transparent research. We also encourage pre-submission enquiries and are always happy to provide a confidential assessment of manuscripts. Digital features and plain language summaries Oncology and Therapy offers a range of additional features designed to increase the visibility, readership and educational value of the journal’s content. Each article is accompanied by key summary points, giving a time-efficient overview of the content to a wide readership. Articles may be accompanied by plain language summaries to assist readers who have some knowledge of, but not in-depth expertise in, the area to understand the scientific content and overall implications of the article. The journal also provides the option to include various types of digital features including animated abstracts, video abstracts, slide decks, audio slides, instructional videos, infographics, podcasts and animations. All additional features are peer reviewed to the same high standard as the article itself. If you consider that your paper would benefit from the inclusion of a digital feature, please let us know. Our editorial team are able to create high-quality slide decks and infographics in-house, and video abstracts through our partner Research Square, and would be happy to assist in any way we can. For further information about digital features, please contact the journal editor (see ‘Contact the Journal’ for email address), and see the ‘Guidelines for digital features and plain language summaries’ document under ‘Submission guidelines’. Preprints We encourage posting of preprints of primary research manuscripts on preprint servers, authors'' or institutional websites, and open communications between researchers whether on community preprint servers or preprint commenting platforms. Posting of preprints is not considered prior publication and will not jeopardize consideration in our journals. Please see here for further information on preprint sharing: https://www.springer.com/gp/authors-editors/journal-author/journal-author-helpdesk/submission/1302#c16721550 Peer Review Process Upon submission, manuscripts are assessed by the editorial team to ensure they fit within the aims and scope of the journal and are also checked for plagiarism. All suitable submissions are then subject to a comprehensive single-blind peer review. Reviewers are selected based on their relevant expertise and publication history in the subject area. The journal has an extensive pool of editorial and advisory board members who have been selected to assist with peer review based on the afore-mentioned criteria. At least two extensive reviews are required to make the editorial decision, with the exception of some article types such as Commentaries, Editorials and Letters which are generally reviewed by one member of the Editorial Board. Where reviewer recommendations are conflicted, the editorial board will be contacted for further advice and a presiding decision. Manuscripts are then either accepted, rejected or authors are required to make major or minor revisions (both reviewer comments and editorial comments may need to be addressed). Once a revised manuscript is re-submitted, it is assessed along with the responses to reviewer comments and if it has been adequately revised it will be accepted for publication. Accepted manuscripts are then copyedited and typeset by the production team before online publication. Appeals against decisions following peer review are considered on a case by case basis and should be sent to the journal editor. Copyright Oncology and Therapy''s content is published open access under the Creative Commons Attribution-Noncommercial License, which allows users to read, copy, distribute, and make derivative works for non-commercial purposes from the material, as long as the author of the original work is cited. The author assigns the exclusive right to any commercial use of the article to Springer. For more information about the Creative Commons Attribution-Noncommercial License, click here: http://creativecommons.org/licenses/by-nc/4.0 Publication Fees Upon acceptance of an article, authors will be required to pay the mandatory Rapid Service Fee of £3650/€4500/$5100. The journal will consider fee discounts for developing countries and this is decided on a case by case basis. Open Access All articles published by Oncology and Therapy are published open access Contact For more information about the journal, including pre-submission enquiries, please contact managing editor Lydia Alborn at lydia.alborn@springer.com.